Quick View
| Metric | Current Period | Same Period Prior Year | YoY |
|---|---|---|---|
| Revenue | ¥14.80B | ¥14.65B | +1.0% |
| Operating Income | ¥1.04B | ¥0.97B | +6.8% |
| Ordinary Income | ¥1.07B | ¥1.12B | −3.9% |
| Net Income | ¥2.39B | ¥0.79B | +204.1% |
| ROE | 22.1% | 9.3% | - |
Executive Summary
Although the Company recorded increases in revenue and operating income during the current period, the substantial increase in net income was primarily attributable to the non-recurring gain on the sale of fixed assets and should be distinguished from an expansion in recurring earnings power. Revenue was ¥14.80B (+1.0% YoY), operating income was ¥1.04B (+6.8% YoY), and the operating margin was 7.0%. Meanwhile, ordinary income declined to ¥1.07B (△3.9% YoY) due to an increase in non-operating expenses, while net income increased significantly to ¥2.39B (+204.1% YoY) owing to extraordinary income that included a ¥2.52B gain on the sale of fixed assets. The fact that operating income grew faster than revenue is positive; however, it is important to assess the Company’s underlying earnings power excluding the boost to net income.
Factors Affecting Performance
【Revenue】Revenue increased modestly by +1.0% YoY to ¥14.80B. By segment, the core Chemicals Business secured higher revenue of ¥12.63B (+2.5% YoY), while the Various Salts Business posted lower revenue of ¥2.17B (△6.6% YoY). The Chemicals Business accounted for 85.4% of total revenue and therefore has a significant impact on overall performance.
【Profit and Loss】Operating income increased by +6.8% YoY to ¥1.04B, exceeding the revenue growth rate, and the operating margin was 7.0%. The increase in profit appears to have been supported by maintaining a gross margin of 28.6% while limiting the SG&A ratio to 21.5%. Ordinary income was ¥1.07B (△3.9% YoY), primarily because non-operating expenses, including ¥0.05B in interest expenses, exceeded non-operating income of ¥0.16B. Net income was ¥2.39B (+204.1% YoY), but this was primarily attributable to the non-recurring gain on the sale of fixed assets of ¥2.52B; excluding the ¥0.11B loss on disposal, the underlying extraordinary gain or loss also made a positive contribution. Overall, the Company recorded increases in revenue and profit, but net income growth was heavily dependent on non-recurring factors.
Segment Analysis
Segment profit was ¥1.78B for the Chemicals Business (+0.1% YoY) and ¥0.08B for the Various Salts Business (+32.8% YoY). The Chemicals Business maintained a high segment profit margin of 14.1% and is the core business, accounting for approximately 95.6% of total segment profit of ¥1.86B. Although the Various Salts Business experienced a revenue decline, its profit margin improved, possibly reflecting progress in reviewing its cost structure. Corporate expenses and other adjustments totaled ¥0.82B, representing the reconciliation from total segment profit to consolidated operating income of ¥1.04B.
Key Financial Indicators
【Profitability】The operating margin was 7.0%, an improvement from the prior year, although it cannot be considered a high level of profitability for a manufacturer. The net margin of 16.1% appears high on the surface but does not reflect underlying performance because it includes the gain on the sale of fixed assets. ROE was 22.1%, based on a DuPont decomposition comprising a net margin of 16.1%, total asset turnover of 0.713x, and financial leverage of 1.92x. The high ROE was largely attributable to the temporary increase in net income.【Cash Flow Quality】Although cash flow statement data has not been disclosed, accounts receivable of ¥5.48B accounted for 26.4% of total assets, and DSO was extended to 101 days. The tie-up of working capital may be delaying the conversion of earnings into cash.【Investment Efficiency】Total asset turnover of 0.713x represents a level at which a certain degree of asset efficiency is being achieved.【Financial Soundness】The equity ratio was 52.1%, improving from the equivalent of 44.4% in the prior year (net assets of ¥8.50B / total assets of ¥22.47B). Short-term liquidity was sound, with a current ratio of 170.0% and a quick ratio of 147.8%; the Debt/Capital ratio was 19.0% against interest-bearing debt of ¥2.54B, indicating no excessive reliance on borrowing.
Cash Flow Analysis
Because cash flow statement figures have not been disclosed, funding trends are analyzed based on changes in the balance sheet. Cash and deposits increased to ¥2.12B from ¥1.70B in the prior year, indicating an expansion in financial capacity. On the other hand, accounts receivable increased significantly to ¥5.48B from ¥3.99B, intensifying the tie-up of working capital. Accounts payable increased to ¥2.76B from ¥2.33B, indicating that funding adjustments on the procurement side also progressed. Interest-bearing debt, comprising short-term and long-term debt, declined to approximately ¥2.54B, and the proceeds secured from the sale of fixed assets may have contributed to debt reduction. Overall, although cash levels improved, the increase in accounts receivable and its impact on cash efficiency require monitoring.
Earnings Quality
A substantial portion of net income for the current period was generated not by recurring business operations but by the non-recurring ¥2.52B gain on the sale of fixed assets. Of profit before tax of ¥3.45B, extraordinary income of ¥2,519 million represented a significant proportion; excluding this item, the profit level would have been close to ordinary income of ¥1.07B. Non-operating income comprised small items such as ¥0.01B in dividend income, while non-operating expenses were primarily ¥0.05B in interest expenses, with no unusual factors evident in non-operating income and expenses. Comprehensive income was ¥2.39B, almost equal to net income of ¥2.39B, indicating that divergences arising from foreign currency translation adjustments or valuation differences on securities were limited. Accordingly, the quality of earnings for the current period is highly dependent on extraordinary income, and from the next fiscal period onward, it is appropriate to evaluate the Company based on recurring earnings power, namely operating income and ordinary income.
Earnings Forecast and Guidance
Progress against the full-year forecast was 64.6% for revenue, 57.6% for operating income, and 61.3% for ordinary income, all below the standard Q3 progress level of 75%. Meanwhile, net income attributable to owners of the parent had already exceeded the full-year forecast, with a progress rate of 108.5%; however, this was attributable to the gain on the sale of fixed assets and does not indicate progress in recurring earnings. Achieving the full-year forecast will require an additional operating income contribution of approximately ¥0.76B in Q4, making the relatively slow progress in operating income a key focus going forward.
Shareholder Returns
The full-year dividend forecast is ¥60 per share, while the Q2 dividend was ¥25. Based on net income of ¥2.39B, the payout ratio is low at approximately 2.4%; however, care is required when interpreting the payout ratio because net income includes the gain on the sale of fixed assets. As operating cash flow has not been disclosed, dividend cash coverage cannot be assessed, but the level of cash and deposits of ¥2.12B suggests that there should be no impediment to continuing dividend payments for the time being.
Risk Factors
-
Prolonged collection of accounts receivable: DSO is extended at 101 days, and accounts receivable account for 26.4% of total assets (¥5.48B). Delays in collection could lead to the tie-up of working capital and increased credit risk.
-
Dependence on non-recurring factors in earnings: Of net income of ¥2.39B, ¥2.52B was attributable to the gain on the sale of fixed assets, exceeding the level of recurring earnings power. If extraordinary income of a similar scale is not recorded in subsequent periods, net income may decline significantly due to the absence of this contribution.
-
Business concentration risk: The Chemicals Business accounts for approximately 95.6% of segment profit, resulting in high dependence on raw material and energy prices as well as supply and demand trends. Revenue in the Various Salts Business declined by △6.6% YoY, and weak demand may persist.
Industry Benchmark (For Reference; Compiled by the Company)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 7.0% | 8.6% (4.3%–12.7%) | −1.6pt |
| Net Margin | 16.2% | 6.4% (2.8%–10.3%) | +9.7pt |
The operating margin was slightly below the industry median, while the net margin was substantially above the industry median due to the impact of extraordinary income.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 1.0% | 3.3% (-2.1%–8.9%) | −2.3pt |
The revenue growth rate was below the industry median, confirming sluggish top-line growth.
Source: Compiled by the Company
Key Points from the Financial Results
-
Operating income increased by +6.8% YoY, exceeding revenue growth of +1.0%, suggesting an improvement in the earnings structure; however, the operating margin of 7.0% was below the industry median of 8.6%.
-
The substantial increases in net income and ROE were attributable to the gain on the sale of fixed assets. Progress in operating income and ordinary income, which reflect recurring earnings power, was 57.6% and 61.3%, respectively, below standard levels relative to the full-year forecast.
-
Accounts receivable increased significantly from the prior year, with DSO reaching 101 days. Collection status and trends in working capital efficiency will be key areas for monitoring.
This report is an earnings analysis document automatically generated by AI based on XBRL financial results summary data. It does not constitute a recommendation to invest in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available financial results data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q3 results showed modest improvement in underlying operations but a sharp, non-recurring uplift in reported earnings. Revenue increased 1.0% YoY to ¥14.80bn. Operating income rose 6.8% YoY to ¥1.04bn. The operating margin improved by 40bp to 7.0%, from 6.6% a year earlier. Gross profit increased to ¥4.23bn and the gross margin expanded by approximately 70bp to 28.6%. This indicates that the improvement in operating income was principally supported by better gross profitability, despite only limited sales growth. SG&A expenses rose 2.3% YoY to ¥3.19bn, exceeding revenue growth and partly constraining operating leverage. Ordinary income declined 3.9% YoY to ¥1.07bn, as the reduction in non-operating income more than offset the operating-income improvement. Reported profit attributable to owners surged 205.3% YoY to ¥2.39bn. However, the primary driver was a ¥2.52bn extraordinary gain on sales of fixed assets. Extraordinary losses were ¥0.14bn, including ¥0.11bn of fixed-asset disposal losses and ¥0.004bn of impairment. Consequently, reported net income, the 16.1% net margin, and the 29.4% annualized ROE substantially overstate recurring profitability. The quality-alert measure shows one-time items at 110.3% of net income, confirming that the earnings increase was asset-sale-led rather than operational. The balance sheet strengthened materially, with total equity rising 27.2% YoY to ¥10.81bn and total liabilities falling 28.7% YoY to ¥9.95bn. Liquidity is sound, reflected in a 170.0% current ratio and 147.8% quick ratio. The principal operational watch item is receivables, which increased 37.5% YoY to ¥5.48bn and correspond to elevated annualized DSO of about 101 days. Full-year sales and operating-income guidance remains achievable but Q3 progress is below the normal 75% seasonal benchmark, while reported net-income progress already exceeds the full-year target because of the extraordinary gain.
Profitability Analysis
The reported DuPont ROE is 29.4%, comprising a 16.1% net profit margin, 0.950x asset turnover, and 1.92x financial leverage. The dominant driver is the net margin rather than turnover or leverage, but that margin is distorted by the ¥2.52bn gain on sale of fixed assets. The five-factor analysis further illustrates this distortion: the interest burden is 3.332x because profit before tax of ¥3.45bn exceeded EBIT of ¥1.04bn, not because financing costs are favorable in an economic sense. By contrast, the operating business generated a 7.0% EBIT margin, which improved from approximately 6.6% in the prior-year period. Gross margin expanded to 28.6% from about 27.9%, a favorable 70bp movement that supported the 6.8% operating-income growth. Segment performance was led by the Chemical Products business, the core business by operating-income contribution: revenue increased 2.5% YoY to ¥12.63bn and segment profit was broadly flat at ¥1.78bn. The Various Salts business recorded revenue of ¥2.17bn, down 6.6% YoY, while segment profit increased to ¥0.81bn from ¥0.61bn. Segment profitability before corporate-cost allocation was therefore concentrated in Chemical Products, although its segment-profit growth was limited. Unallocated corporate costs declined to ¥0.82bn from ¥0.87bn, contributing to the increase in consolidated operating income. SG&A grew 2.3%, faster than revenue growth of 1.0%, which limits the durability of margin expansion unless gross-margin improvement continues. Interest coverage remains strong at 21.58x, with interest expense of only ¥0.48bn relative to EBIT. The 30.6% effective tax rate is broadly normal, while the 0.691 tax burden is marginally below the 0.70 reference level. On an annualized basis, the reported ROE should not be interpreted as normalized return generation because the annualized flow includes a large realized asset gain.
Growth Assessment
Sales growth was subdued at 1.0% YoY, with Chemical Products expanding but Various Salts declining. The Chemical Products business generated ¥12.63bn of external revenue, representing approximately 85% of consolidated sales, making its volume, pricing and input-cost performance central to group growth. Various Salts contributed ¥2.17bn of revenue and remains smaller but showed improved segment profitability despite lower sales. Consolidated operating income grew faster than revenue, demonstrating some favorable gross-margin and corporate-cost leverage. However, SG&A growth exceeded sales growth, so operating-income momentum remains dependent on continued cost-of-sales discipline rather than top-line scale alone. The full-year forecast calls for revenue of ¥22.90bn, operating income of ¥1.80bn, ordinary income of ¥1.75bn and profit attributable to owners of ¥2.20bn. Q3 cumulative revenue represents 64.6% of the full-year forecast, 10.4 percentage points below the standard 75% Q3 progress rate. Operating-income progress is 57.6%, 17.4 percentage points below the standard rate. Ordinary-income progress is 61.3%, also below the normal Q3 run rate. These shortfalls imply a required Q4 revenue contribution of ¥8.10bn and operating income of ¥0.76bn. Profit attributable to owners has already reached 108.5% of the full-year forecast, but this is explained by the fixed-asset sale gain and does not indicate equivalent outperformance in recurring earnings. The annual operating-income forecast implies a 7.9% full-year margin, requiring a stronger Q4 margin than the 7.0% achieved cumulatively. The outlook therefore depends on a meaningful Q4 operational acceleration, particularly in the core Chemical Products business, rather than on additional exceptional gains.
Financial Health
Financial health improved substantially year on year. Total equity rose to ¥10.81bn from ¥8.50bn, while total liabilities decreased to ¥9.95bn from ¥13.97bn. Equity now represents 52.1% of total assets, compared with 37.8% in the prior-year period. The current ratio of 170.0% and quick ratio of 147.8% indicate that current assets of ¥11.06bn adequately cover current liabilities of ¥6.51bn. Working capital is positive at ¥4.55bn. Interest-bearing debt totals ¥2.54bn, equivalent to a conservative debt-to-equity ratio of 0.92x and debt-to-capital ratio of 19.0%. Cash and deposits of ¥2.12bn cover short-term loans of ¥0.50bn by 4.24x. The short-term debt ratio is 19.7%, limiting near-term refinancing pressure. Interest coverage of 21.58x provides substantial headroom against current financing costs. Accounts receivable increased by ¥1.50bn, or 37.5% YoY, to ¥5.48bn and now accounts for 26.4% of total assets; collection discipline is therefore important to liquidity quality. PPE declined by ¥3.11bn, or 28.3% YoY, to ¥7.85bn, principally consistent with the large gain on sale of fixed assets recorded in the income statement. Long-term debt declined to ¥2.04bn from ¥2.62bn and short-term loans fell to ¥0.50bn from ¥0.85bn, reinforcing the deleveraging trend. Asset retirement obligations of ¥1.05bn equal approximately 1.1% of total liabilities, below the 2% chemical-industry caution benchmark and manageable relative to the balance sheet. Treasury shares of ¥1.05bn represent 5.0% of total assets and modestly reduce reported shareholders' equity. The balance sheet is sound, although the loss of productive assets through disposal and the elevated receivables balance warrant monitoring.
Notable B/S Changes
Accounts receivable: +¥1.50bn (+37.5%) to ¥5.48bn - increase materially exceeded revenue growth and drove annualized DSO to approximately 101 days; collection quality is a key cash-conversion risk. Property, plant and equipment: -¥3.11bn (-28.3%) to ¥7.85bn - consistent with the ¥2.52bn gain on sale of fixed assets; monitor the impact of asset disposals on future operating capacity and replacement needs. Short-term loans: -¥0.35bn (-41.2%) to ¥0.50bn - lowers refinancing pressure and supports the improvement in short-term liquidity. Retained earnings: +¥2.26bn (+26.2%) to ¥10.86bn - strengthened equity, although the increase was substantially supported by non-recurring asset-sale income. Total liabilities: -¥4.02bn (-28.7%) to ¥9.95bn - significant deleveraging and a higher equity ratio improved balance-sheet resilience. Land: -¥0.66bn (-58.3%) to ¥0.47bn - a major component of the fixed-asset movement and likely related to the realized gain on asset sales. Construction in progress: -¥2.92bn (-96.8%) to ¥0.10bn - indicates completion, transfer, or disposal of a major project; the low remaining construction-in-progress balance suggests a limited visible investment pipeline.
Cash Flow Quality
Cash-flow quality cannot be quantified from the available figures because operating cash flow, investing cash flow, financing cash flow, capital expenditure and free cash flow are not reported in the supplied financial data. Earnings quality is nevertheless clearly affected by the composition of profit. Profit before tax was ¥3.45bn, compared with ordinary income of ¥1.07bn, with the difference principally arising from the ¥2.52bn fixed-asset sale gain. The extraordinary gain exceeded profit attributable to owners of ¥2.39bn, and the quality-alert metric places one-time items at 110.3% of net income. This means cash conversion from reported net income should not be assumed without confirmation of the cash proceeds, tax treatment and use of proceeds from the asset disposal. Working-capital quality is also a key consideration: accounts receivable increased ¥1.50bn YoY while revenue rose only ¥0.15bn. Annualized DSO is approximately 101 days, materially above the 60-day warning threshold and indicating potentially slower customer collections, contract timing effects, or a greater concentration of sales near period-end. Inventories were ¥1.44bn, broadly stable relative to the prior-year period, and annualized inventory days are approximately 37 days based on annualized cost of sales, which is efficient for a chemical manufacturer. Accounts payable were ¥2.76bn; annualized payable days are approximately 71 days, providing supplier financing support but exceeding the typical 30-60 day range. The resulting annualized cash-conversion cycle is approximately 67 days, within the broad healthy range but dependent on reducing the elevated receivables cycle. The key cash-flow question for subsequent periods is whether the asset-sale proceeds and improved profitability translate into cash generation after working-capital movements and investment needs.
Dividend Sustainability
The company paid an interim Q2 dividend of ¥25 per share. The full-year forecast indicates a dividend of ¥60 per share, implying a ¥35 per-share year-end dividend if the interim payment is maintained. Based on forecast EPS of ¥1,095.78, the implied dividend-only payout ratio is approximately 5.5%, which is conservative. The calculated Q2 payout ratio of 2.4% relative to Q3 cumulative reported profit also indicates low near-term earnings distribution. Retained earnings increased 26.2% YoY to ¥10.86bn, providing a substantial accounting buffer for dividends. Balance-sheet leverage is moderate, and liquidity ratios are strong, which supports financial capacity for the forecast dividend. However, reported Q3 profit is heavily supported by a fixed-asset sale gain; dividend assessment should therefore focus on recurring operating cash generation rather than the reported 16.1% net margin. The forecast dividend appears modest relative to forecast earnings and balance-sheet capacity, but free-cash-flow coverage cannot be verified from the available data. No share-buyback amount is reported, so a total return ratio cannot be assessed.
Risk Assessment
Business risks include Chemical-products demand, selling prices and input-cost spreads remain the principal earnings drivers because the Chemical Products segment accounts for approximately 85% of consolidated revenue., The Various Salts business recorded a 6.6% YoY revenue decline, creating risk that segment-profit improvement may be difficult to sustain if volume weakness persists., Chemical manufacturing faces exposure to raw-material and energy-price volatility, environmental regulation, plant safety incidents and product-quality issues., Annualized DSO of approximately 101 days creates collection and customer-credit risk; receivables grew 37.5% YoY despite only 1.0% sales growth., The substantial disposal of fixed assets may reduce future operating capacity or alter the productive-asset base, depending on the nature of the assets sold..
Financial risks include Reported net income and annualized ROE are materially distorted by a ¥2.52bn extraordinary gain on sale of fixed assets, which exceeds net income., Q3 operating-income progress is 57.6% of full-year guidance, 17.4 percentage points below the standard 75% Q3 benchmark, requiring a strong Q4., Accounts payable imply annualized DPO of approximately 71 days; while supportive of liquidity, prolonged payment terms could affect supplier relationships if they rise further., PPE declined 28.3% YoY, and future maintenance or replacement requirements cannot be assessed from the reported figures..
Key concerns include Highest priority: earnings normalization after the asset-sale gain. Recurring operating income was only ¥1.04bn at Q3, versus reported profit attributable to owners of ¥2.39bn., Highest priority: receivable collection. The 101-day DSO quality alert is materially above the 60-day warning level and is the clearest operating-cash-flow risk., Medium priority: achieving the implied Q4 operating-income requirement of ¥0.76bn to meet full-year guidance., Medium priority: sustaining gross-margin improvement while SG&A growth continues to exceed revenue growth..
Investment Implications
Key takeaways include Underlying operating performance improved moderately: revenue rose 1.0%, operating income rose 6.8%, and operating margin expanded 40bp to 7.0%., Reported earnings growth is not representative of recurring profitability because a ¥2.52bn gain on sale of fixed assets drove the majority of Q3 profit., The balance sheet strengthened through lower liabilities and higher equity, with 170.0% current ratio, 0.92x debt-to-equity and 21.58x interest coverage., Receivables are the most important near-term quality issue, rising 37.5% YoY and producing annualized DSO of approximately 101 days., Full-year operating guidance requires a stronger Q4 than the cumulative Q3 run rate, while net-income guidance has already been surpassed due to extraordinary income..
Metrics to watch include Chemical Products segment revenue growth and segment-profit margin, Various Salts sales recovery and profit durability, Gross margin and SG&A-to-sales trend, Quarter-end receivables balance, annualized DSO and credit-loss experience, Q4 operating income versus the ¥0.76bn required to meet full-year guidance, Cash deployment and future earnings impact of the fixed-asset disposal, PPE level, replacement investment and environmental obligations.
Regarding relative positioning, The company combines a sound liquidity and solvency profile with a mid-single-digit operating margin that remains below the 8%-plus level generally associated with stronger profitability. Its reported annualized 29.4% ROE is not an appropriate indicator of recurring relative performance because it is dominated by a large asset-sale gain. Relative operating positioning should instead be judged on the 7.0% operating margin, modest 1.0% sales growth, segment mix, and improvement in receivables collection.